AsianFin — Merck announced on Tuesday that it would delay shipments of its HPV vaccine, Gardasil, to China until at least mid-2025, citing weak discretionary spending. This decision has impacted the company's full-year forecast and caused a sharp 11% drop in its shares during early trading.
Gardasil, which protects against cancers linked to the human papillomavirus (HPV), has been one of Merck's leading growth drivers alongside Keytruda. However, the vaccine's sales, which had previously seen strong growth in China, have significantly slowed since the second quarter of 2024.
Explore more exclusive insights at nextfin.ai.
